Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VCN-01 by Theriva Biologics for High-Grade Glioma: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
VCN-01 by Theriva Biologics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Theriva Biologics's VCN-01?
VCN-01 is an oncolytic virus commercialized by Theriva Biologics, with a leading Phase II program in Retinoblastoma. According to Globaldata,...